AUA 2016: Radium-223 re-treatment: Experience from an international, multicenter, prospective study in patients with castration-resistant prostate cancer and bone metastases - Session Highlights

San Diego, California ( Dr. Luke Nordquist presented data evaluating the value of Radium-223 re-treatment in castration-resistant prostate cancer and bone metastases.

Radium-223 (Ra-223) treatment is beneficial in patients with castration-resistant prostate cancer (CRPC) with bone metastases. The authors sought to report the safety and efficacy of Radium-223 re-treatment from an international prospective open-label trial in metastatic CRPC patients (NCT01934790).

The study enrolled CRPC patients with more than 2 bony metastases who previously received Radium 223 treatment and progressed after inital treatment. No additional chemotherapies were given, but other agents were permitted (e.g. abiraterone).

The primary outcome of this study was safety, and time to radiographic bone progression, time to PSA progression, and radiographic progression-free survival (rPFS) based on MRI/CT and bone scans performed q 3 mo were included.

44 patients were included in the study and 66% of these patients received all 6 treatments.

73% of the patients failed either abiraterone or enzalutamide.

7% of the patients experienced grade 3 or 4 adverse events. Only 1 patient was reported to have radiographic progression.

Time to biochemical progression was 2 month and median rPFS was nearly 10 months. The authors concluded that Radium 223 re-treatment is safe and well tolerated. Re-treatment with radium-233 it provided continued stability in the bony disease.


Presented By: Luke Nordquist, MD.

Written By: Miki Haifler MD. Fox Chase Cancer Center, Philadelphia, PA. at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA